Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors
ConditionSolid Tumors
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorNanolattix Biotechnology Co., Ltd.
About this trial
RT01-89Zr is a TF-targeting radiopharmaceutical diagnostic agent. This trial aims to evaluate the safety, biodistribution, dosimetry, and imaging characteristics of RT01-89Zr as a PET/CT tracer in patients with malignant solid tumors that highly express the TF target.
Eligibility criteria
Qualifiers
Patients of either gender, ages 18-75 (including 18 and 75);
ECOG Performance Status: 0 or 1;
Confirmed as a solid tumor by histopathology or cytology;
At least one primary or metastatic lesion confirmed by conventional imaging；
Disqualifiers
Patients who are unable to complete a PET/CT scan (including those who cannot lie flat, have claustrophobia, or have fear of radiation, etc.);
Those who have received radiopharmaceuticals before administration and whose discontinuation duration does not exceed 5 half-lives;
Participants who have participated in other clinical trials within the past 3 months (except for clinical trials of investigational drugs discontinued for more than 5 half-lives, and assessed by the investigator as having no impact on endpoint evaluation and participant safety), or who plan to participate during the trial;
Acute systemic diseases and electrolyte disorders;
Trial design
Treatments tested in this trial
- RT01-89Zr
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov